SeekingAlpha · Aug 9, 2026
Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-09. The following slide deck was published by Recursion Pharmaceuticals, Inc.
RX
NASDAQ · RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
Healthcare · Biotechnology
$3.31
Up+$0.02 (+0.61%)
Updated Aug 14, 2026, 2:48 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.83B
- P/E ratio
- -2.94
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $7.18
- Volume
- 10.7M
- Avg. volume
- 43.4M
Price performance
RXRX price history
1M range · 21 trading sessions · Daily adjusted prices
RXRX closed at $3.31 after 21 trading sessions, up 9.60% for the selected period.
- Last close
- $3.31
- Period change
- +9.60%
- Period low
- $2.89
- Period high
- $3.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $3.31 | $3.35 | $3.27 | $3.31 | 10.7M |
| Aug 12, 2026 | $3.37 | $3.38 | $3.26 | $3.29 | 10.31M |
| Aug 11, 2026 | $3.32 | $3.42 | $3.27 | $3.35 | 11.01M |
| Aug 10, 2026 | $3.20 | $3.36 | $3.19 | $3.29 | 14.03M |
| Aug 7, 2026 | $3.2541 | $3.265 | $3.18 | $3.22 | 9.36M |
| Aug 6, 2026 | $3.13 | $3.26 | $3.115 | $3.18 | 14.79M |
| Aug 5, 2026 | $3.08 | $3.23 | $3.01 | $3.17 | 17.46M |
| Aug 4, 2026 | $3.265 | $3.36 | $3.21 | $3.31 | 21.58M |
| Aug 3, 2026 | $3.03 | $3.20 | $3.00 | $3.18 | 14.72M |
| Jul 31, 2026 | $3.09 | $3.105 | $2.95 | $3.00 | 15.33M |
| Jul 30, 2026 | $2.99 | $3.04 | $2.95 | $3.04 | 10.41M |
| Jul 29, 2026 | $3.03 | $3.09 | $2.945 | $2.97 | 17.95M |
| Jul 28, 2026 | $2.975 | $3.05 | $2.86 | $3.05 | 24.4M |
| Jul 27, 2026 | $3.03 | $3.13 | $2.99 | $3.01 | 21.72M |
| Jul 24, 2026 | $3.04 | $3.09 | $2.92 | $2.96 | 16.53M |
| Jul 23, 2026 | $2.925 | $3.03 | $2.92 | $3.01 | 18.83M |
| Jul 22, 2026 | $3.04 | $3.07 | $2.97 | $2.98 | 15.21M |
| Jul 21, 2026 | $2.90 | $3.08 | $2.90 | $3.08 | 14.87M |
| Jul 20, 2026 | $2.945 | $2.955 | $2.84 | $2.89 | 20.81M |
| Jul 17, 2026 | $2.96 | $3.02 | $2.93 | $2.945 | 19.35M |
| Jul 16, 2026 | $3.25 | $3.27 | $2.975 | $3.02 | 40.17M |
Latest RXRX news
The latest Smart Investors Daily articles mentioning RXRX.
Stock researchCompany · Overview
RXRX research
Overview
Company profile and research snapshot.
Company profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | Needham | Buy | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 5, 2026
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsNajat Khan - CEO, President & DirectorVicki...
Benzinga · Aug 5, 2026
Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per
SeekingAlpha · Jun 12, 2026
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on RXRX stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
